ABL1 and leukemia: C57Bl/10 mice were transplanted with p190-BCR-ABL1 low-density bone marrow (LDBM) cells, stratified into five groups post leukemia development, and administered either vehicle, 0.25 or 0.5 mM IODVA1, 0.5 mM imatinib, or the combination 0.25 mM IODVA1 + 0.5 mM imatinib via osmotic pumps.